--- title: "Lilly's Next-Gen Weight-Loss Drug Clears Trial With Near-Bariatric Surgery Results" type: "News" locale: "en" url: "https://longbridge.com/en/news/287231633.md" description: "Eli Lilly's next-generation obesity drug, retatrutide, has shown promising Phase 3 trial results, achieving weight loss comparable to bariatric surgery. In the TRIUMPH-1 trial, participants lost an average of 28.3% of body weight with the 12 mg dose over 80 weeks. Despite some mild side effects, the drug's efficacy positions it as a strong competitor in the weight-loss market. Lilly shares rose 1% in premarket trading, while competitor Novo Nordisk's shares fell slightly." datetime: "2026-05-21T13:42:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287231633.md) - [en](https://longbridge.com/en/news/287231633.md) - [zh-HK](https://longbridge.com/zh-HK/news/287231633.md) --- # Lilly's Next-Gen Weight-Loss Drug Clears Trial With Near-Bariatric Surgery Results Eli Lilly reported positive Phase 3 results for its next-generation obesity drug, **retatrutide, which delivered weight-loss results on par with** those of bariatric surgery. In the TRIUMPH-1 trial, overweight adults, but without diabetes, achieved **meaningful weight loss across all tested doses after 80 weeks**: - 12 mg dose: average weight loss of 70.3 pounds, or 28.3% of body weight. - 9 mg dose: average weight loss of 64.4 pounds, or 25.9%. - 4 mg dose: average weight loss of 47.2 pounds, or 19% Ahead of the results, _RBC Capital Markets analyst Trung Huynh_ said the **key success range** would be 28% to 30% weight loss. Lilly's 12 mg dose appears to have cleared the low end of Huynh's bar, with patients losing an average of 28.3% of their body weight over 80 weeks. "**We're in a zone that's historically been associated with bariatric surgery, and you're getting it with a medicine**," Kenneth Custer, president of Lilly Cardiometabolic Health, told Bloomberg in an interview. Custer added, "I think we can definitively check the box" based on the data that "retatrutide moves the goalpost on max efficacy." Retatrutide is a **first-in-class triple hormone receptor agonist**targeting **GIP, GLP-1, and glucagon**, positioning it as potentially superior to current weight-loss drugs such as Lilly's Zepbound, Novo Nordisk's Wegovy, and copycat GLP-1s. Lilly noted some downsides to taking the drug in the trial: > _Events of dysesthesia and urinary tract infections were generally mild to moderate, the majority resolved during treatment, and most participants continued taking retatrutide_ In markets, Lilly shares rose about 1% in premarket trading in New York, while shares of the Wegovy competitor, Novo Nordisk, traded in Copenhagen, fell slightly. **Latest in the GLP-1 space:** - HIMS Shares Plunge As Pivot To Branded GLP-1s Weighs On Outlook The **key question** is whether bariatric surgery begins to lose favor among patients as next-generation obesity medications replicate, or come close to replicating, surgery-level weight loss without an invasive procedure. ### Related Stocks - [LLY.US](https://longbridge.com/en/quote/LLY.US.md) - [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md) - [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md) - [NVOX.US](https://longbridge.com/en/quote/NVOX.US.md) - [RY.US](https://longbridge.com/en/quote/RY.US.md) - [NVO.US](https://longbridge.com/en/quote/NVO.US.md) - [HIMS.US](https://longbridge.com/en/quote/HIMS.US.md) ## Related News & Research - [](https://longbridge.com/en/news/287237352.md) - [Eli Lilly Retatrutide 12 Mg Achieved 30.3% Average Weight Loss At 104 Weeks In Extension](https://longbridge.com/en/news/287203984.md) - [FOCUS-Lower cost Novo, Lilly weight-loss pills draw patients from compounded drugs, doctors say](https://longbridge.com/en/news/287195854.md) - [Eli Lilly (LLY) Is Up 6.0% After Obesity Drug Data And $4.5B Manufacturing Push - Has The Bull Case Changed?](https://longbridge.com/en/news/286629257.md) - [Trump purchased Eli Lilly stock as policies favored its drugs](https://longbridge.com/en/news/286791021.md)